soul trial oral semaglutide cardiovascular outcomes results 2024 nejm A emulation in Nature Medicine shows that treatment with and tirzepatide showed similar levels of benefit on in people at elevated cardiovascular risk with obesity and diabetes. Link Long-term kidney outcomes of semaglutide

You will be prescribed medications to help relieve these symptoms

The complexity of distinguishing between provoked and unprovoked VTE, coupled with gaps in obesity definition and assessment still complicates a tailored risk assessment of VTE risk

Los nutricionistas responden

A comprehensive phase 3 program is ongoing to evaluate efficacy, safety, and cardiovascular/renal outcomes in people with obesity and/or T2D

Understanding your GLP-1 receptor and GIPR genetic predispositions may help contextualize why one dual-receptor agonist or single-receptor option suits your metabolic profile better

Several patterns appear consistently: Loss of lean muscle mass Inadequate protein intake Nutrient deficiencies, particularly vitamin D and magnesium This matters because muscle mass plays a direct role in supporting skeletal health